Nachrichten zur Angiodynamics Inc. Aktie

Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?

Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.…

AngioDynamics dürfte im freundlichen Marktumfeld rasch am Allzeithoch notieren

AngioDynamics (ANGO) durchläuft einen Transformationsprozess und will sich auf wachstumsstarke Medizintechnikmärkte wie Prostatakrebs oder Thrombektomie konzentrieren. Das adressierbare Marktpotenzial... …

AngioDynamics im Pivotal-Point-Check: 22 % Umsatzwachstum in Q3 - NanoKnife und Thrombektomie treiben MedTech-Segment an!

Strategischer Fokus auf die Erweiterung des MedTech-Angebots führt zu einem beeindruckenden Umsatzwachstum von 22,2 % in diesem Segment. Kreditlinie…

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

…

AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 123.08% and 2%, respectively, for the quarter ended February 2025. Do the…

AngioDynamics (ANGO) Down 14.2% Since Last Earnings Report: Can It Rebound?

AngioDynamics (ANGO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

AngioDynamics startet nach Quartalszahlen und FDA-Zulassung für NanoKnife durch - Canaccord stuft auf 15 USD (Buy)!

AngioDynamics (ANGO) befindet sich laut CEO Jim Clemmer in diesem Jahr an einem wichtigen Wendepunkt für die Unternehmensentwicklung. In…

AngioDynamics: A Surgical Approach To Market Growth

…

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

…

AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 63.64% and 2.36%, respectively, for the quarter ended November 2024. Do the…

ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife

AngioDynamics latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient…

Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?

AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend…

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Heres is How to Trade

The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after…

[Latest] Global Embolic Protection Device Market Size/Share Worth USD 3,562.2 Million by 2033 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE

AngioDynamics announces the receipt of CPT Category I code for IRE technology.…

AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise

AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med…

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

…

AngioDynamics, Inc. 2025 Q1 - Results - Earnings Call Presentation

…

ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe

AngioDynamics RECOVER-AV trial evaluates the AlphaVac F1885 Systems safety and efficacy in treating acute pulmonary embolism in Europe.…

Does AngioDynamics (ANGO) Have the Potential to Rally 77.03% as Wall Street Analysts Expect?

The mean of analysts price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly…

AngioDynamics: Lumpy Progress Is Still Progress

…

AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the…

Earnings call: AngioDynamics sees steady growth in FY 2024 results By Investing.com

Earnings call: AngioDynamics sees steady growth in FY 2024 results…

AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript

…

AngioDynamics (ANGO) AlphaVac System Gets CE Mark Approval

AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range…

AngioDynamics: A Story To Monitor

…

Earnings call: AngioDynamics posts mixed Q3 results, focuses on growth By Investing.com

Earnings call: AngioDynamics posts mixed Q3 results, focuses on growth…

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.…

AngioDynamics (ANGO) AlphaVac Gets FDA Nod for PE Treatment

AngioDynamics (ANGO) announces the FDAs approval of its AlphaVac F1885 System, which is likely to expand the range of therapy…

AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript

…

AngioDynamics (ANGO) Settles Patent Litigations With BD

AngioDynamics (ANGO) announces its settlement agreement with BDs affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.…

dpa-AFX ProFeed